The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

Sun, December 14, 2025 at 4:58 PM UTC As the AI trade gets overheated and calls for some sort of bursting of the AI bubble grow louder, it might make sense to look to opportunities to be had within ...

This was a new position; the IBB stake now accounts for 8.7% of Florin Court Capital LLP’s 13F AUM Top five holdings after the filing: ICLN: $16.6 million (13.0% of AUM) IBB: $11.1 million (8.7% of ...

Biotech-based exchange-traded fund (“ETF”) iShares Biotechnology ETF IBB rallied 30.2% over the past six months (as of Oct. 15, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 26.5%). Year to date ...

The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to ...

BIB seeks 2x the daily return of the Nasdaq Biotechnology Index, amplifying both gains and losses through leverage. A higher expense ratio reflects leverage costs and management fees; a 24 bps ...

Kentucky-based Aristides Capital sold 28,467 shares of IBB in the third quarter. The shares were worth an estimated $3.60 million. The move marked a full exit from the position, which was previously ...

Sold 24,270 shares of IBB; estimated trade value of $3.50 million based on quarterly average pricing. Net position value decreased by $3.50 million. Represents a 3.27% shift in 13F reportable assets ...